NCT06880107 Genetic Variants of Annexin A2 and Cryptogenic Stroke
| NCT ID | NCT06880107 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Annexin A2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-04-08 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2025-04-08 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke. ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease. Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.
Eligibility Criteria
Inclusion Criteria: * Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients * Age from 18 years old Exclusion Criteria: * Transient ischemic attack * Pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06880107 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Annexin A2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06880107 currently recruiting?
Yes, NCT06880107 is actively recruiting participants. Contact the research team at salle.valery@chu-amiens.fr for enrollment information.
Where is the NCT06880107 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT06880107 clinical trial?
NCT06880107 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 240 participants.